Corbus Pharmaceuticals to Join August Investor Conferences

NORWOOD, Mass., July 30, 2024 – Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) has declared that its CEO, Yuval Cohen, Ph.D., will engage in two upcoming investor conferences in August. Dr. Cohen will offer a corporate update and engage in one-on-one meetings with investors at these events.

The first event is the BTIG Virtual Biotechnology Conference, scheduled for August 5-6, 2024. This conference will be conducted by invitation only, featuring one-on-one investor meetings. Interested investors are advised to reach out to their BTIG representatives for attendance details.

The second event is the Wedbush PacGrow Healthcare Conference, to be held on August 13-14, 2024. Similar to the BTIG conference, this event is also invite-only, and will include one-on-one and small group investor meetings. Investors wishing to attend should contact their Wedbush representatives for further information.

Corbus Pharmaceuticals Holdings, Inc. is a company focused on precision oncology with a broad portfolio aimed at combating serious illnesses through innovative scientific methods targeting well-known biological pathways. The company’s pipeline features three notable projects:

1. CRB-701: This next-generation antibody drug conjugate targets Nectin-4 expression on cancer cells, administering a cytotoxic payload to the targeted cells.
2. CRB-601: An anti-integrin monoclonal antibody that inhibits the activation of TGFβ, which is expressed on cancer cells.
3. CRB-913: A highly peripherally restricted CB1 receptor inverse agonist designed for treating obesity.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!